Media coverage about GlycoMimetics (NASDAQ:GLYC) has trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. GlycoMimetics earned a news impact score of 0.05 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 44.2274778122711 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
GlycoMimetics (NASDAQ GLYC) opened at $24.19 on Monday. The stock has a market capitalization of $830.63, a PE ratio of -19.51 and a beta of 3.40. GlycoMimetics has a 1-year low of $3.82 and a 1-year high of $26.05.
GLYC has been the topic of several research analyst reports. Zacks Investment Research upgraded GlycoMimetics from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a report on Monday, November 13th. Cowen restated a “buy” rating on shares of GlycoMimetics in a report on Wednesday, December 6th. SunTrust Banks raised their price target on GlycoMimetics to $32.00 and gave the company a “buy” rating in a report on Tuesday, December 12th. Jefferies Group reiterated a “buy” rating and issued a $21.00 price target on shares of GlycoMimetics in a report on Wednesday, December 20th. Finally, BidaskClub upgraded GlycoMimetics from a “hold” rating to a “buy” rating in a report on Thursday, January 11th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $22.67.
WARNING: This report was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/3222926/glycomimetics-glyc-given-daily-news-impact-score-of-0-05.html.
GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.